Get started
Work

LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)

Year: 2020
Type: conference-abstract
DOI: 10.1016/j.annonc.2020.08.2316
Authors: J. Baena Espinar, V. Torri, J. Whisenant, F.R. Hirsch, J. Rogado, J. de Castro Carpeño, B. Halmos, G.L. Ceresoli, A. Gomez Rueda, M. Tiseo, E. Felip, M. Majem Tarruella, I. Monnet, U. Tapan, H. Wakelee, L-C. Huang, M.C. Garassino, S. Peters, L. Horn, M. Hellmann
Institutions: Hospital Universitario 12 De Octubre, Mario Negri Institute for Pharmacological Research, Vanderbilt University, Vanderbilt University Medical Center, Mount Sinai Health System, Hospital Universitario de La Princesa, Hospital Universitario La Paz, Albert Einstein College of Medicine, Montefiore Einstein Comprehensive Cancer Center, Humanitas Gavazzeni, Hospital Universitario Ramón y Cajal, University of Parma, Vall d'Hebron Hospital Universitari, Hospital de Sant Pau, Hôpital Intercommunal de Créteil, Boston Medical Center, Stanford Cancer Institute, Stanford University, Fondazione IRCCS Istituto Nazionale dei Tumori, Centre Hospitalier Universitaire Vaudois, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Alexion Pharmaceuticals, F. Hoffmann-La Roche, Regeneron Pharmaceuticals, Exelixis, National Comprehensive Cancer Network, INOVIO Pharmaceuticals, Incyte, Eisai, Astellas Pharma, Ipsen, Genentech, EMD Serono, Merck Sharp and Dohme, Foundation Medicine, Daiichi Sankyo Europe
OpenAlex ID: W3087927078
Cites:
Cited by: 14
Related to: 10